Icovamenib clinical trials
Also written BMF-219.
How each study uses icovamenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the icovamenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Biomea Fusion Inc. (7)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test icovamenib.
- Mar 2027Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsPhase 2 · Biomea Fusion Inc.
- Jun 2027Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyPhase 2 · Biomea Fusion Inc.
Studies
Open first, then newest update. How each study uses icovamenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyRecruitingPhase 2Biomea Fusion Inc.NCT07502508Written as icovamenib 100 mg
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)CompletedPhase 1/2Biomea Fusion Inc.NCT05731544Written as BMF-219
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsActive, not recruitingPhase 2Biomea Fusion Inc.NCT07502495Written as icovamenib 100mg
- Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusCompletedPhase 2Biomea Fusion Inc.NCT06152042Written as BMF-219
- Food Effect Study in Healthy VolunteersCompletedPhase 1Biomea Fusion Inc.NCT07254286Written as Icovamenib
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedPhase 1Biomea Fusion Inc.NCT05153330Written as BMF-219
- Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal CancerTerminatedPhase 1Biomea Fusion Inc.NCT05631574Written as BMF-219
Codes
What other systems call icovamenib · ClinicalTrials.gg INT014557
- UNII (FDA) 2Z737MY35AICOVAMENIBOne source FDA
- NCI Thesaurus C185864IcovamenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2Z737MY35A | ICOVAMENIB | One source FDA |
| NCI Thesaurus | C185864 | Icovamenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.